Glucosamine is a non-nutrient, non-mineral enhancement generally used to calm osteoarthritis and joint pain.1 Glucosamine is firmly directed in most European nations, where it is just sold with a medicine. In any case, in different nations, for example, the United States and Australia, it is a prominent dietary enhancement and around 20% of grown-ups expend it every day
The UK Biobank is a national wellbeing asset in the United Kingdom intended to improve the aversion, analysis, and treatment of a wide scope of ailments and to advance wellbeing all through society.2223 The UK Biobank selected around 500 000 members matured 40-69 of every 2006-10 from the nation over.
Information from 502 616 members were accessible for our examination. We rejected members with CVD at gauge (n=32 187) and those with fragmented information on the utilization of glucosamine (n=4390). Our last investigation included 466 039 members.
There were 466 039 participants without CVD at baseline who completed a questionnaire on supplement use, which included glucosamine. These participants were enrolled from 2006 to 2010 and were followed up to 2016.
The Main outcome measures Incident CVD events, including CVD death, coronary heart disease, and stroke.
Results found that during a median follow-up of seven years, there were 10 204 incident CVD events, 3060 CVD deaths, 5745 coronary heart disease events, and 3263 stroke events. After adjustment for age, sex, body mass index, race, lifestyle factors, dietary intakes, drug use, and other supplement use, glucosamine use was associated with a significantly lower risk of total CVD events (hazard ratio 0.85, 95% confidence interval 0.80 to 0.90), CVD death (0.78, 0.70 to 0.87), coronary heart disease (0.82, 0.76 to 0.88), and stroke (0.91, 0.83 to 1.00).
To conclude, Habitual use of glucosamine supplement to relieve osteoarthritis pain might also be related to lower risks of CVD events.